Navigation Links
MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting

MOUNTAIN VIEW, Calif., June 05, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster presentation, which was accepted as a late-breaker, is entitled Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo(TM) Inhaler), Poster ID S77, and will be presented on Saturday, June 9, 2007 from 12:00 to 1:00pm CDT. In addition, the Company also has three other poster presentations available for viewing at the conference.

    Details for the three presentations are as follows:

    -- Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel

       System (Tempo(TM) Inhaler); Poster ID F07; June 8, 12:30 to 1:30pm CDT.

    -- Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites

       Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel

       System (Tempo(TM) Inhaler); Poster ID F08; June 8, 12:30 to 1:30pm CDT.

    -- (5-HT, Adrenergic, Dopaminergic) Receptor Binding: Implications for

       Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System

       (Tempo(TM) Inhaler); Poster ID S67; June 9, 12:00 to 1:00pm CDT.

MAP Pharmaceuticals is developing a series of inhaled respiratory and systemic drug product candidates delivered with the Tempo inhaler. The first of these product candidates is MAP0004, a systemic migraine treatment designed to provide faster and more consistent relief than current non-injectable therapeutics. In early human studies, MAP0004 delivered therapeutic blood levels within ten minutes of inhalation, similar to those seen only after intravenous injection. This performance will potentially allow MAP0004 to mimic both the efficacy and blood levels of inj ectable therapy, offering fast relief without injections. By providing rapid onset with a novel formulation of a proven compound (dihydroergotamine mesylate), MAP Pharmaceuticals seeks to meet the treatment needs of the large, underserved population of migraine sufferers with MAP0004.

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and neurological diseases. The Company has announced positive results from Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at

CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122,

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/1/2015)... Texas , Dec. 1, 2015 /PRNewswire/ ...  announced today that top-line data from its ... telotristat etiprate in treating carcinoid syndrome in ... with the clinical benefit observed in its ... designed as a companion to TELESTAR primarily ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 Ampio ... New York Stock Exchange has established January 5, 2016 as ... its stockholders of the shares of Common Stock of ... (1) share of Aytu common stock for every five ... the record date, December 1, 2015. The distribution date will ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... defines and segments the concerned market with analysis and ... orthobiologics report defines and segments the concerned ... According to the Market Research Report "North American ... Bone Growth Factors & Spinal Stimulation, Stem Cell Therapy, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical laser ... devices for sale in the United States. Clarity is a Superior Dual Wavelength ... lasers, into a single platform that is easy to own and operate. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users can ... customization, the possibilities are truly endless, all with a click of a mouse. Each ... flip, horizontal flip, depth of field and more, all within Final Cut Pro X. ...
(Date:11/30/2015)... ... 2015 , ... Third Molar SEO , one of ... launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, founder and ... the benefits that its SEO services provide to dentists and why Third Molar ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... The ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized with ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:11/30/2015)... ... , ... Until now, the St. Louis Fetal Care Institute used ... Study) trial. One of these exclusion criteria was a BMI above 34.9. According to ... is considered normal, 25 - 29.9 is overweight and above 30 is obese. , ...
Breaking Medicine News(10 mins):